309 related articles for article (PubMed ID: 26113417)
1. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
[TBL] [Abstract][Full Text] [Related]
3. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
[TBL] [Abstract][Full Text] [Related]
5. A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats.
Aberdein D; Munday JS; Gandolfi B; Dittmer KE; Malik R; Garrick DJ; Lyons LA;
Mamm Genome; 2017 Feb; 28(1-2):47-55. PubMed ID: 27770190
[TBL] [Abstract][Full Text] [Related]
6. FcRγ promotes T cell apoptosis in Fas-deficient mice.
Juvet SC; Thomson CW; Kim EY; Joe B; Adeyi O; Zhang L
J Autoimmun; 2013 May; 42():80-93. PubMed ID: 23313147
[TBL] [Abstract][Full Text] [Related]
7. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
[TBL] [Abstract][Full Text] [Related]
8. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
Marega LF; Teocchi MA; Dos Santos Vilela MM
Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
[TBL] [Abstract][Full Text] [Related]
11. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation.
Revel-Vilk S; Fischer U; Keller B; Nabhani S; Gámez-Díaz L; Rensing-Ehl A; Gombert M; Hönscheid A; Saleh H; Shaag A; Borkhardt A; Grimbacher B; Warnatz K; Elpeleg O; Stepensky P
Clin Immunol; 2015 Jul; 159(1):84-92. PubMed ID: 25931386
[TBL] [Abstract][Full Text] [Related]
13. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
14. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype.
Boggio E; Aricò M; Melensi M; Dianzani I; Ramenghi U; Dianzani U; Chiocchetti A
Pediatrics; 2013 Oct; 132(4):e1052-8. PubMed ID: 24043286
[TBL] [Abstract][Full Text] [Related]
15. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
[TBL] [Abstract][Full Text] [Related]
16. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
Nagata S
J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
[TBL] [Abstract][Full Text] [Related]
17. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
18. [Non-malignant, non-infectious lymphoproliferation: challenges in the diagnosis and treatment of autoimmune lymphoproliferative syndrome].
Molnár E; Kovács G; Varga L; Tasnády S; Bors A; Tankó L; Csabán D; Kapócs K; Nemes-Nagy Z; Andrikovics H
Orv Hetil; 2022 Jan; 163(4):123-131. PubMed ID: 35066491
[TBL] [Abstract][Full Text] [Related]
19. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
[TBL] [Abstract][Full Text] [Related]
20. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
